Coralan (ivabradine), a
medication from a novel class
of therapy for heart failure
(selective sinus node inhibitors)
shown to significantly reduce the
risk of cardiovascular death and
hospitalisation due to worsening
heart failure, will become available
on the PBS 01 Dec.
Coralan will be reimbursed for
the treatment of symptomatic
moderate to severe chronic heart
failure in patients with a resting
heart rate of 77 beats per minute
(bpm) or more.
“Coralan is one of the very few
therapies shown to significantly
improve both survival and quality
of life in this patient group,” said
Professor Henry Krum, Director
of Monash University’s Centre
for Cardiovascular Research and
Education in TherapeuticsThe above article was sent to subscribers in Pharmacy Daily's issue from 07 Nov 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Nov 13
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.